Natalizumab treatment reduces endothelial activity in MS patients

被引：32

作者：

Millonig, Alban ^{[1
]}

Hegen, Harald ^{[1
]}

Di Pauli, Franziska ^{[1
]}

Ehling, Rainer ^{[1
]}

Gneiss, Claudia ^{[1
]}

Hoelzl, Martina ^{[1
]}

Kuenz, Bettina ^{[1
]}

Lutterotti, Andreas ^{[1
]}

Rudzki, Dagmar ^{[1
]}

Berger, Thomas ^{[1
]}

Reindl, Markus ^{[1
]}

Deisenhammer, Florian ^{[1
]}

机构：

[1] Innsbruck Med Univ, Dept Neurol, A-6020 Innsbruck, Austria

来源：

JOURNAL OF NEUROIMMUNOLOGY | 2010年 / 227卷 / 1-2期

关键词：

PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; SOLUBLE ADHESION MOLECULES; RELAPSING MULTIPLE-SCLEROSIS; ALPHA-CONVERTING ENZYME; INTERFERON-BETA; CELL-ADHESION; MONOCLONAL-ANTIBODIES; CONTROLLED TRIAL; VCAM-1; BLOOD;

D O I：

10.1016/j.jneuroim.2010.07.012

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Vascular cell adhesion molecule-1 a ligand for leukocyte very late activating antigen-4 is a key player in leukocyte extravasation in MS lesions. Natalizumab a monoclonal antibody against VLA-4 blocks this interaction. VCAM-1 and its soluble form are up-regulated during endothelial activation in MS. We investigated the effect of Natalizumab on sVCAM-1 and VLA-4 on circulating leukocytes in MS patients. Natalizumab reduced levels of sVCAM-1 compared to controls (256 vs. 597 ng/mL). This effect was sustained and only reversed in patients with neutralizing antibodies against Natalizumab. Correspondingly Natalizumab diminished VLA-4 on leukocyte subsets. Our findings indicate that Natalizumab reduces transmigration not only by blocking VLA-4 but also by down-regulating VCAM-1. (c) 2010 Elsevier B.V. All rights reserved.

引用

页码：190 / 194

页数：5

共 37 条

[11] Comparative study of four different assays for the detection of binding antibodies against interferon-β [J].

Gneiss, C. ;

Brugger, M. ;

Millonig, A. ;

Fogdell-Hahn, A. ;

Rudzki, D. ;

Hillert, J. ;

Berger, T. ;

Reindl, M. ;

Deisenhammer, F. .

MULTIPLE SCLEROSIS, 2008, 14 (06) :830-836

[12] Interferon-β-1a induces increases in vascular cell adhesion molecule:: implications for its mode of action in multiple sclerosis [J].

Graber, J ;

Zhan, M ;

Ford, D ;

Kursch, F ;

Francis, G ;

Bever, C ;

Panitch, H ;

Calabresi, PA ;

Dhib-Jalbut, S .

JOURNAL OF NEUROIMMUNOLOGY, 2005, 161 (1-2) :169-176

[13] CIRCULATING ADHESION MOLECULES AND TUMOR-NECROSIS-FACTOR RECEPTOR IN MULTIPLE-SCLEROSIS - CORRELATION WITH MAGNETIC-RESONANCE-IMAGING [J].

HARTUNG, HP ;

REINERS, K ;

ARCHELOS, JJ ;

MICHELS, M ;

SEELDRAYERS, P ;

HEIDENREICH, F ;

PFLUGHAUPT, KW ;

TOYKA, KV .

ANNALS OF NEUROLOGY, 1995, 38 (02) :186-193

[14] Production of MMPs in human cerebral endothelial cells and their role in shedding adhesion molecules [J].

Hummel, V ;

Kallmann, BA ;

Wagner, S ;

Füller, T ;

Bayas, A ;

Tonn, JC ;

Benveniste, EN ;

Toyka, KV ;

Rieckmann, P .

JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY, 2001, 60 (04) :320-327

[15] SUPPRESSION AND PROMOTION OF TUMOR-GROWTH BY MONOCLONAL-ANTIBODIES TO ERBB-2 DIFFERENTIALLY CORRELATE WITH CELLULAR UPTAKE [J].

HURWITZ, E ;

STANCOVSKI, I ;

SELA, M ;

YARDEN, Y .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1995, 92 (08) :3353-3357

[16] Cytokines and adhesion molecules in multiple sclerosis patients treated with interferon-β1b [J].

Jensen, J ;

Krakauer, M ;

Sellebjerg, F .

CYTOKINE, 2005, 29 (01) :24-30

[17] Cytokine-induced modulation of cellular adhesion to human cerebral endothelial cells is mediated by soluble vascular cell adhesion molecule-1 [J].

Kallmann, BA ;

Hummel, V ;

Lindenlaub, T ;

Ruprecht, K ;

Toyka, KV ;

Rieckmann, P .

BRAIN, 2000, 123 :687-697

[18] The effects of natalizumab on inflammatory mediators in multiple sclerosis: prospects for treatment-sensitive biomarkers [J].

Khademi, M. ;

Bornsen, L. ;

Rafatnia, F. ;

Andersson, M. ;

Brundin, L. ;

Piehl, F. ;

Sellebjerg, F. ;

Olsson, T. .

EUROPEAN JOURNAL OF NEUROLOGY, 2009, 16 (04) :528-536

[19] Brief report - Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis [J].

Kleinschmidt-DeMasters, BK ;

Tyler, KL .

NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (04) :369-374

[20] Cell surface bound and soluble adhesion molecules in CSF and blood in multiple sclerosis: correlation with MRI-measures of subclinical disease severity and activity [J].

Kraus, J ;

Engelhardt, B ;

Chatzimanolis, N ;

Bauer, R ;

Tofighi, J ;

Kuehne, BS ;

Laske, C ;

Stolz, E ;

Frielinghaus, P ;

Schaefer, C ;

Blaes, F ;

Traupe, H ;

Kaps, M ;

Oschmann, P .

JOURNAL OF NEUROIMMUNOLOGY, 2002, 122 (1-2) :175-185

← 1 2 3 4 →